On October 18, 2022, William Mann, Ph.D., president and chief operating officer of NeuBase Therapeutics, Inc., notified the company of his intent to resign from the company, effective October 31, 2022. Dr. Mann's resignation is not a result of any disagreement with the company on any matter relating to the company's policies or procedures.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.378 USD | -3.20% | 0.00% | -48.93% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+41.04% | 5.09TCr | |
-0.40% | 4.21TCr | |
+49.62% | 4.2TCr | |
-7.20% | 2.92TCr | |
+12.83% | 2.6TCr | |
-21.45% | 1.89TCr | |
+7.04% | 1.32TCr | |
+24.52% | 1.22TCr | |
+30.49% | 1.22TCr |